Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 (COVID-19) Lower Respiratory Tract Disease in a B-cell Acute Lymphoblastic Leukemia (ALL) Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 (COVID-19) Lower Respiratory Tract Disease in a B-cell Acute Lymphoblastic Leukemia (ALL) Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir
复制标题
DOI：
10.1093/cid/ciac868
复制
发表时间：
2022-11-03
影响因子：
11.8
通讯作者：
Corey, Lawrence
中科院分区：
文献类型：
--
作者：
Ford, Emily S.;Simmons, William;Corey, Lawrence
1例b细胞急性淋巴细胞白血病（ALL）和严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）患者在感染5个月后，尽管有单克隆抗体、静脉注射（IV）瑞德西韦和长期口服类固醇，但仍出现持续性进行性肺炎并病毒血症。20天的尼马特利韦/利托那韦和10天的静脉注射瑞德西韦使患者完全康复。
A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.